Dual antiplatelet therapy duration after myocardial infarction
Ticagrelor should generally not be stopped 4 months after an acute coronary syndrome myocardial infarction because default dual antiplatelet therapy (DAPT) with aspirin plus a potent P2Y12 inhibitor is recommended for a minimum of 12 months after ACS unless exceptions apply. [1] The dental procedure should typically be managed without interruption of single or dual antiplatelet therapy rather than stopping ticagrelor. [2]
Dental extraction while receiving ticagrelor
Minor oral surgery such as uncomplicated tooth extraction is generally managed by continuing antiplatelet therapy with local hemostatic measures rather than interrupting ticagrelor. [2] A guidance recommendation for dental patients taking single or dual antiplatelet drugs supports treatment without interrupting antiplatelet medication for dental treatment. [3]
Medication selection algorithm for peri-dental management
- Continue DAPT through the dental extraction when bleeding can be controlled with local measures (ticagrelor + aspirin). [2]
- If interruption is being considered because of exceptionally high procedural bleeding risk, cardiology input should be obtained before discontinuing antiplatelet therapy. [2]
Monotherapy versus combination therapy during dental procedures
Continuation of dual antiplatelet therapy for minor oral surgery is supported by evidence showing clinically similar bleeding rates across single- and dual-antiplatelet comparisons, with bleeding managed using local measures. [2]
Initiation and interruption thresholds
A 4-month post-MI time point does not meet the default ACS exception window for shortening DAPT, because the default is at least 12 months of potent P2Y12 inhibitor–based DAPT after ACS. [1]
Common pitfalls to avoid
Stopping ticagrelor prematurely to reduce procedural bleeding risk is discouraged because the risk of thromboembolism from interrupting post-stent/ACS antiplatelet therapy can outweigh the consequences of prolonged bleeding that can be controlled locally. [2]
Targets and goals of therapy
The goal is to preserve antiplatelet protection during the first 12 months after ACS while controlling bleeding at the extraction site using local hemostatic techniques rather than interrupting ticagrelor. [1], [2]